<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>311</serviceExecutionTime><Drug id="56257"><DrugName>CVX-060</DrugName><DrugSynonyms><Name><Value>CVX-060</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>angiopoietin-2 inhibitors (cancer), CovX</Value></Name><Name><Value>Ang-2 inhibitors (cancer), CovX</Value></Name><Name><Value>CVX-37</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>CVX-87</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>CVX-32</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>CovX-060</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>angiopoietin-2 inhibitors (cancer), Pfizer</Value></Name><Name><Value>PF-4856884</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>PF-04856884</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1010777">CovX Pharmaceuticals Inc</CompanyOriginator><CompaniesSecondary><Company id="1010777">CovX Pharmaceuticals Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="56257" type="Drug"><TargetEntity id="456010" type="siDrug">PF-4856884</TargetEntity></SourceEntity><SourceEntity id="1010777" type="Company"><TargetEntity id="4297129941" type="organizationId">Covx Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="4250" type="ciIndication"><TargetEntity id="10050513" type="MEDDRA"/><TargetEntity id="3229" type="siCondition"/></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"/></SourceEntity><SourceEntity id="725" type="ciIndication"><TargetEntity id="1164" type="siCondition"/></SourceEntity><SourceEntity id="61" type="Action"><TargetEntity id="885" type="Mechanism">Angiogenesis Inhibitors</TargetEntity></SourceEntity><SourceEntity id="14323" type="Action"><TargetEntity id="3168" type="Mechanism">Anti-ANGPT2 (Angiopoietin 2)</TargetEntity></SourceEntity><SourceEntity id="PTGT-03654" type="ciTarget"><TargetEntity id="16397075482853" type="siTarget">Angiopoietin-2</TargetEntity><TargetEntity id="8067" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="4250">Metastatic renal cell carcinoma</Indication><Indication id="651">Cancer</Indication><Indication id="725">Solid tumor</Indication></IndicationsSecondary><ActionsPrimary><Action id="14323">Angiopoietin ligand-2 inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="61">Angiogenesis inhibitor</Action><Action id="55685">Anticancer monoclonal antibody</Action></ActionsSecondary><Technologies><Technology id="84">Protein fusion</Technology><Technology id="169">Monoclonal antibody humanized</Technology><Technology id="740">Infusion</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="171">Monoclonal antibody conjugated</Technology><Technology id="648">Intravenous formulation</Technology></Technologies><LastModificationDate>2018-06-04T16:51:28.000Z</LastModificationDate><ChangeDateLast>2018-05-23T00:00:00.000Z</ChangeDateLast><AddedDate>2006-10-17T13:08:44.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1010777" linkType="Company"&gt;CovX&lt;/ulink&gt;, a wholly owned subsidiary of &lt;ulink linkID="18767" linkType="Company"&gt;Pfizer&lt;/ulink&gt;, was developing   CVX-060 (CovX-060, PF-4856884), the lead from a series of antiangiogenic angiopoietin-2 (Ang-2) inhibiting recombinant humanized  mAb fusion compounds,  created using the proprietary CovX-Body technology,  for the potential iv infusion treatment of cancer, including renal cell carcinoma (RCC)  [&lt;ulink linkID="731860" linkType="Reference"&gt;731860&lt;/ulink&gt;], [&lt;ulink linkID="861931" linkType="Reference"&gt;861931&lt;/ulink&gt;], [&lt;ulink linkID="883033" linkType="Reference"&gt;883033&lt;/ulink&gt;], [&lt;ulink linkID="947491" linkType="Reference"&gt;947491&lt;/ulink&gt;], [&lt;ulink linkID="1060563" linkType="Reference"&gt;1060563&lt;/ulink&gt;]. In September 2009, a phase I/II trial was initiated in patients with RCC in the US; in November 2011, a US phase II trial  in metastatic RCC was initiated [&lt;ulink linkID="1060563" linkType="Reference"&gt;1060563&lt;/ulink&gt;], [&lt;ulink linkID="1262440" linkType="Reference"&gt;1262440&lt;/ulink&gt;]. In February 2013, Pfizer closed the CovX research unit  [&lt;ulink linkID="1385029" linkType="Reference"&gt;1385029&lt;/ulink&gt;]. Later that month, Pfizer listed the program as in phase I on the company pipeline; however, at that time, it was presumed that  the closure of CovX  precluded further development   of  the  program and that CVX-060 remained discontinued  [&lt;ulink linkID="1385029" linkType="Reference"&gt;1385029&lt;/ulink&gt;], [&lt;ulink linkID="1387629" linkType="Reference"&gt;1387629&lt;/ulink&gt;] and, in May 2013, Pfizer listed the program as discontinued [&lt;ulink linkID="1418340" linkType="Reference"&gt;1418340&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;CovX is also developing another antiangiogenesis mAb fusion, &lt;ulink linkID="56255" linkType="Drug"&gt;CVX-045&lt;/ulink&gt;, for the potential treatment of solid tumors [&lt;ulink linkID="731866" linkType="Reference"&gt;731866&lt;/ulink&gt;], and was investigating other angiopoietin-2 inhibitors including CVX-37. However,  by January 2008 CVX-37 was not mentioned on the company pipeline and it was presumed CVX-060 was the lead compound as it entered clinical studies [&lt;ulink linkID="864433" linkType="Reference"&gt;864433&lt;/ulink&gt;], [&lt;ulink linkID="864247" linkType="Reference"&gt;864247&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In November 2011, a randomized, crossover, open-label, phase II trial (&lt;ulink linkID="81132" linkType="Protocol"&gt;NCT01441414&lt;/ulink&gt;; B1131004) was initiated in the US, to evaluate CVX-060 in combination with &lt;ulink linkID="39209" linkType="Drug"&gt;axitinib&lt;/ulink&gt; versus axitinib alone  in patients (expected n = 165) with metastatic RCC who had received one prior systemic regimen. The primary endpoints were safety profile over 4 months and progression-free survival over 3 years. At that time, the trial was estimated to complete in December 2013 [&lt;ulink linkID="1262440" linkType="Reference"&gt;1262440&lt;/ulink&gt;]. In June 2013, data were presented from 18 patients at the 49th ASCO meeting in Chicago, IL.  Overall, two patients showed confirmed partial response, two patients showed unconfirmed partial response, ten patients had stable disease and one patient had progressive disease [&lt;ulink linkID="1425703" linkType="Reference"&gt;1425703&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2009, a non-randomized, open-label, phase I/II  study (&lt;ulink linkID="60562" linkType="Protocol"&gt;NCT00982657&lt;/ulink&gt;; CVX-060-102; B1131001) was initiated in patients with advanced RCC (expected n = 124) in the US, to assess the safety and efficacy of CVX-060 in combination with &lt;ulink linkID="12973" linkType="Drug"&gt;sunitinib&lt;/ulink&gt;. The study was still recruiting in November 2009 and was expected to be complete by July 2013. In January 2012, the trial was ongoing, but was no longer recruiting participants [&lt;ulink linkID="1060563" linkType="Reference"&gt;1060563&lt;/ulink&gt;]. In October 2015, the trial was terminated [&lt;ulink linkID="1060563" linkType="Reference"&gt;1060563&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2008, a non-randomized, dose-escalation, open-label, single-group assessing safety, phase I trial (&lt;ulink linkID="51398" linkType="Protocol"&gt;NCT00879684&lt;/ulink&gt;; B1131002, CVX-060-101) began in patients (expected n = 34) in the US with advanced solid tumors. The primary endpoints were evaluating the safety and tolerability of CVX-060 as weekly iv infusions and identify and characterize treatment-related adverse events. The trial  would evaluate the  pharmacokinetic and pharmacodynamics of the drug [&lt;ulink linkID="864247" linkType="Reference"&gt;864247&lt;/ulink&gt;], [&lt;ulink linkID="1320957" linkType="Reference"&gt;1320957&lt;/ulink&gt;].  In June 2010, results from this study were presented at the 46th ASCO meeting in Chicago, IL.  Dose proportional increases in serum Ang-2 levels were observed in patients. PK results supported once-weekly dosing and  CVX-060 up to 15 mg/kg/week was well tolerated [&lt;ulink linkID="1103917" linkType="Reference"&gt;1103917&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In September 2009, preclinical data were presented at the Fourth IBC Beyond Antibodies Conference in San Diego. CVX-060 had an increased half-life from 0.1 to 80 h, which was associated with an 98-fold improvement in in vitro potency. CVX-060 was found to be as efficacious as &lt;ulink linkID="8047" linkType="Drug"&gt;bevacizumab&lt;/ulink&gt; in a colon cancer xenograft model, in which it was also found to improve the response to &lt;ulink linkID="2871" linkType="Drug"&gt;irinotecan&lt;/ulink&gt; or &lt;ulink linkID="2953" linkType="Drug"&gt;docetaxel&lt;/ulink&gt; when administered together. Targeting both VEGF with bevacizumab and Ang-2 with CVX-060 was also associated with a cooperative benefit in xenograft models [&lt;ulink linkID="1047701" linkType="Reference"&gt;1047701&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2007, preclinical data on another Ang-2 specific CovX-Body, CVX-37, were presented at the 98th AACR meeting in Los Angeles, CA. This compound was produced by fusing a chemically modified peptide to the specific Fab-binding site of a specially designed antibody. CVX-37 was shown to inhibit any Ang-2 interaction with Tie-2 in a competition ELISA, with an IC50 value of 0.34 nM, but no effect was observed between the interaction of Ang-1with Tie-2. The anti-tumor activity of CVX-37 was assessed in a Colo205 xenograft model, with an iv qw dose of the drug. A significant decrease in tumor volume was observed at 1, 3, and 10 mg/kg.  Histological analysis revealed that CVX-37 increased tumor death more than 2-fold. This study thus demonstrates that the Ang-2 blocker, CVX-37, can effectively decrease Ang-2 protein levels inside the tumor mass, and greatly inhibit tumor growth and angiogenesis [&lt;ulink linkID="784430" linkType="Reference"&gt;784430&lt;/ulink&gt;], [&lt;ulink linkID="787575" linkType="Reference"&gt;787575&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2006, preclinical data were reported at the 14th Annual Biopartnering meeting in London, UK. At that time, the company expected to initiate IND-enabling safety studies in the first quarter of 2007  [&lt;ulink linkID="731858" linkType="Reference"&gt;731858&lt;/ulink&gt;]. CVX-060 was investigated against two other Ang-2 binding CovX-Body mAbs, CVX-32 and CVX-87. All three were found to block interaction between Ang-2 and Tie-2 tyrosine kinase receptor. CVX-87 was shown to reduce density of microvessels and Ang-2 inhibition was shown to dose dependently reduce tumor growth in xenografts of colon tumors. CVX-060 was found to support a favorable dosing regimen through its pharmacokinetic profile [&lt;ulink linkID="731858" linkType="Reference"&gt;731858&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;CovX's core proprietary technology, based on the production of   CovX-Bodies, links a powerful target agent peptide to a small linker molecule, specific to the mAb active binding sites, resulting in a bivalent, potent, high-affinity and long-acting fusion protein [&lt;ulink linkID="731858" linkType="Reference"&gt;731858&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By February 2008, CovX had become a wholly owned subsidiary of Pfizer [&lt;ulink linkID="861931" linkType="Reference"&gt;861931&lt;/ulink&gt;], [&lt;ulink linkID="883033" linkType="Reference"&gt;883033&lt;/ulink&gt;]. &lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1010777">CovX Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="725">Solid tumor</Indication><StatusDate>2013-02-16T00:00:00.000Z</StatusDate><Source id="1385029" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1010777">CovX Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="4250">Metastatic renal cell carcinoma</Indication><StatusDate>2013-02-16T00:00:00.000Z</StatusDate><Source id="1385029" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1010777">CovX Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate>2008-01-02T00:00:00.000Z</StatusDate><Source id="864247" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1010777">CovX Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><StatusDate>2009-09-30T00:00:00.000Z</StatusDate><Source id="1060563" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1010777">CovX Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2006-10-10T00:00:00.000Z</StatusDate><Source id="731858" type="OTHER"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-03654"><Name>Angiopoietin ligand-2</Name><SwissprotNumbers><Swissprot>O15123</Swissprot><Swissprot>O35462</Swissprot><Swissprot>O35608</Swissprot><Swissprot>O77802</Swissprot><Swissprot>Q9BDY7</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><PatentFamilies><PatentFamily id="448411" number="WO-2012007896" title="Multifunctional antibody conjugates"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Pfizer Inc" id="18767"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>